Skip to main content
Premium Trial:

Request an Annual Quote

Sistemic, Roslin Cells Partner to Establish Stem Cell Manufacturing Standards

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sistemic and Roslin Cells today announced a memorandum of understanding to promote technologies to standardize the manufacture of stem cells for use in cell therapy and drug development screening.

Financial and other terms of the MOU were not disclosed.

In a statement, Jim Reid, Sistemic's CEO, said that in its work with clients, the company has found "that there is a general consensus within the stem cell community that the currently available tools and technologies are not truly fit for purpose." He added that Sistemic in collaboration with Roslin will "set the standard for stem cell characterization and quality."

Based in Glasgow, UK, Sistemic develops miRNA-based services and kit-based products for the pharmaceutical, biotechnology, and cell therapy markets. Roslin Cells is a non-profit organization established by the Roslin Institute, with the goal of providing ethically sourced, pluripotent human cells.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.